On March 14, the US Food and Drug Administration (FDA) approved tislelizumabjsgr as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal
squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1
inhibitor.
For more information read the BeiGene announcement.
Posted 3/15/2024